Yesterday, 3 April 2017, Therabel GiEnne Pharma announced the collective dismissal of its employees with the consequent termination of the employment relationship of 86 units due to the cessation of scientific information activity and of the commercial, administrative and logistic support activities.
The Management cites the continuous measures to contain pharmaceutical expenditure as a reason, and Therabel also has a portfolio of products that are no longer covered by patents and as such are exposed to competition from the relative generics.
Against this situation, the press release continues, having assessed the prospect of a drop in turnover and given the notoriety of the products, the company no longer deems scientific information activity necessary.
The company will therefore arrange for the dismissal of 86 employees, of which 65 scientific informants of the drug and 3 area managers.
The Company specifies that there are no patrimonial attributions other than those envisaged by law or contract.
Union meetings will take place next week: Monday in Milan, Tuesday in Rome, Wednesday in Catania.
Press Release Collective.Therabel.dismissal
Ed
Mediolanum Farmaceutici, through its subsidiary Neopharmed Gentili, acquired Therabel Gienne Pharma, the Italian branch of the Dutch Therabel group, on 3 February.
Jean-Michel Robert, president of Therabel, commented: “We are convinced that with its consistent presence in Italy, Mediolanum will enhance its product portfolio as it deserves”, with Therabel. Alessandro DelBono (in the photo on the left), CEO of the Mediolanum Farmaceutici group, said: “The acquisition of Therabel Gienne Pharma allows us to strengthen our presence in strategic areas of the pharmaceutical sector, enriching our portfolio of various products well known to health professionals”.
Dr. Glisenti, Mediolanum Human Resources Manager, was charged with managing the acquisition of Therabel. Dr. Glisenti let it be known in a meeting on 27 March with the trade unions that the acquisition of Therabel does not envisage integration with the other group companies.
Therabel is considered "economically weak", which needs a rationalization with "impossibility of maintaining the structure" starting from the abandonment of the scientific information of the drug. This will lead to "important employment problems" about which there will be communications on April 3 during a meeting with the union representatives (as reported and formalized in yesterday's statement).
A "lean and commercial" structure is envisaged. In addition to the meeting on April 3, another is expected on the 7th. In the meantime, unconfirmed rumors refer to a hypothetical transfer of an ISF line from Mylan to Mediolanum. From a chamber of commerce registration made by a colleague, it would appear that Mediolanum spent 60 million in 2014 and 65 in 2015 under the heading "other", without specifying what else is.
